Skip to main content
رجوع
CHSYF logo

China Medical System Holdings Limited

جودة البيانات: 100%
ذروة شراء
CHSYF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 1.35
KWD 0.00 (0.00%)
القيمة السوقية: 3.28B
نطاق اليوم
KWD 0.93 KWD 1.35
نطاق 52 أسبوعًا
KWD 0.93 KWD 1.64
حجم التداول
110
متوسط 50 يوم / 200 يوم
KWD 1.35 / KWD 1.31
الإغلاق السابق
KWD 1.35

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 2.3 0.3
P/B 0.2 2.9
ROE % 8.6 3.7
Net Margin % 18.1 3.8
Rev Growth 5Y % -1.0 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2028 KWD 1.232
KWD 1.107 – KWD 1.306
 15 B 1
FY2027 KWD 1.008
KWD 0.905 – KWD 1.068
 12 B 1
FY2026 KWD 0.849
KWD 0.763 – KWD 0.900
 10 B 1

النقاط الرئيسية

Revenue declined -1.03% annually over 5 years
Earnings declined -10.45% over the past year
Net margin of 18.13% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 812.64M in free cash flow
P/E of 2.26 — trading at a low valuation

النمو

Revenue Growth (5Y)
-1.03%
Revenue (1Y)7.11%
Earnings (1Y)-10.45%
FCF Growth (3Y)-48.20%

الجودة

Return on Equity
8.60%
ROIC6.37%
Net Margin18.13%
Op. Margin19.22%

الأمان

Debt / Equity
0.04
Current Ratio6.33
Interest Coverage77.77

التقييم

P/E Ratio
2.26
P/B Ratio0.19
EV/EBITDA0.82
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.11% Revenue Growth (3Y) -0.08%
Earnings Growth (1Y) -10.45% Earnings Growth (3Y) -22.27%
Revenue Growth (5Y) -1.03% Earnings Growth (5Y) -16.73%
Profitability
Revenue (TTM) 8.00B Net Income (TTM) 1.45B
ROE 8.60% ROA 7.55%
Gross Margin 71.50% Operating Margin 19.22%
Net Margin 18.13% Free Cash Flow (TTM) 812.64M
ROIC 6.37% FCF Growth (3Y) -48.20%
Safety
Debt / Equity 0.04 Current Ratio 6.33
Interest Coverage 77.77 Dividend Yield 0.03%
Valuation
P/E Ratio 2.26 P/B Ratio 0.19
P/S Ratio 0.41 PEG Ratio -1.51
EV/EBITDA 0.82 Dividend Yield 0.03%
Market Cap 3.28B Enterprise Value 1.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8.00B 7.47B 8.01B 9.15B 8.34B
Net Income 1.45B 1.62B 2.40B 3.26B 3.02B
EPS (Diluted) 0.60 0.67 0.98 1.33 1.22
Gross Profit 5.72B 5.42B 6.08B 7.04B 6.25B
Operating Income 1.54B 1.73B 2.71B 3.55B 3.15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.21B 18.05B 17.73B 17.75B 15.81B
Total Liabilities 1.66B 1.64B 2.17B 3.02B 2.96B
Shareholders' Equity 17.40B 16.31B 15.52B 14.59B 12.75B
Total Debt 690.43M 860.74M 1.30B 1.81B 1.71B
Cash & Equivalents 2.70B 3.71B 4.31B 4.38B 3.39B
Current Assets 9.30B 8.70B 8.79B 8.83B 7.38B
Current Liabilities 1.47B 1.52B 2.05B 2.88B 2.08B

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#702 of 827
23
Value Defensive Investing (Benjamin Graham)
#286 of 709
33

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026